

Supplementary Tables S2A and S2B. Characteristics of patients with LRP and HRP progression (S2A) and oligometastatic (OM) and polymetastatic (PM) progression (S2B) in lung metastasis samples.
Legend: Student's t-test (t-test); two-tailed Fisher's Exact Test (FET); two-tailed non-parametric Mann Whitney Test (MWT); log-rank Mantel-Cox test (Log-rank); *=statistically significant; *ns* = not significant

Supplementary Table S2A					
Patients (#)	Overall Group (N=63)	Cumulative LRP and HRP (N=48)	LRP progression (N=32)	HRP progression (N=16)	p-value
Median age at surgery (Range)	58 (24-83)	58 (26-83)	58 (26-82)	59 (41-83)	0.67 <i>ns</i> (t-test)
Sex					
Female (%)	32	28	21 (75%)	7 (25%)	0.22 <i>ns</i> (FET)
Male (%)	31	20	11 (55%)	9 (45%)	
Primary tumor type					
Gastrointestinal	16	13	8	5	0.74 <i>ns</i> (FET)
Musculoskeletal/Soft Tissue	18	12	9	3	0.73 <i>ns</i> (FET)
Genitourinary	11	7	3	4	0.20 <i>ns</i> (FET)
Head and Neck	8	7	4	3	0.67 <i>ns</i> (FET)
Breast	4	4	4	0	0.29 <i>ns</i> (FET)
Gynecologic	3	3	3	0	0.54 <i>ns</i> (FET)
Hepatobiliary	2	2	1	1	1.0 <i>ns</i> (FET)
Lung	1	0	0	0	1.0 <i>ns</i> (FET)
Histology					
Adenocarcinoma	23	19	16	3	0.06 <i>ns</i> (FET)
Sarcoma	22	15	11	4	0.74 <i>ns</i> (FET)
Renal Cell Carcinoma	7	4	1	3	0.10 <i>ns</i> (FET)
Squamous Cell Carcinoma	3	3	1	2	0.25 <i>ns</i> (FET)
Adenoid Cystic Carcinoma	3	3	2	1	1.0 <i>ns</i> (FET)
Other	5	4	1	3	
Median # metastasis(es) at surgery (Range)	1 (1-5)	1 (1-5)	1 (1-3)	2 (1-5)	0.15 <i>ns</i> (MWT)
Median # of total recurrent metastasis(es) following surgery (Range)	3 (0-10)	1 (0-10)	0 (0-3)	10 (7-10)	<0.0001* (MWT)
Survival (total # alive throughout follow-up/total per group)	31/63	28/48	25/32	3/16	0.0001* (FET)
Median follow-up time (months) (Range)	47 (5-149)	38.5 (5-149)	63.5 (18-149)	18 (5-24)	<0.0001* (Log-rank)

Supplementary Table S2B				
Patients (#)	All (N=63)	OM progression (N=39)	PM progression (N=24)	p-value
Median age at surgery (Range)	58 (24-83)	58 (24-82)	61 (29-83)	0.54 <i>ns</i> (t-test)
Sex				
Female (%)	32	24 (62%)	8 (33%)	0.04* (FET)
Male (%)	31	15 (38%)	16 (67%)	
Primary tumor type				
Gastrointestinal	16	9	7	0.77 <i>ns</i> (FET)
Musculoskeletal/Soft Tissue	18	13	5	0.39 <i>ns</i> (FET)
Genitourinary	11	4	7	0.09 <i>ns</i> (FET)
Head and Neck	8	4	4	0.47 <i>ns</i> (FET)
Breast	4	4	0	0.29 <i>ns</i> (FET)
Gynecologic	3	3	0	0.28 <i>ns</i> (FET)
Hepatobiliary	2	1	1	1.0 <i>ns</i> (FET)
Lung	1	1	0	1.0 <i>ns</i> (FET)
Histology				
Adenocarcinoma	22	17	5	0.10 <i>ns</i> (FET)
Sarcoma	22	16	6	0.28 <i>ns</i> (FET)
Renal Cell Carcinoma	8	2	6	0.05* (FET)
Squamous Cell Carcinoma	3	1	2	0.55 <i>ns</i> (FET)
Adenoid Cystic Carcinoma	3	2	1	1.0 <i>ns</i> (FET)
Other	5	1	4	
Median # metastasis(es) at surgery (Range)	1 (1-5)	1 (1-3)	1.5 (1-5)	0.14 <i>ns</i> (MWT)
Median # of total recurrent metastasis(es) following surgery (Range)	3 (0-10)	0 (0-10)	10 (7-10)	<0.0001* (MWT)
Survival (total # alive throughout follow-up/total per group)	31/63	27/39	4/24	7.02E-5* (FET)
Median follow-up time (months) (Range)	47 (5-149)	59 (18-149)	25.5 (5-74)	<0.0001* (Log-rank)